Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/09546634.2020.1801974 http://scihub22266oqcxt.onion/10.1080/09546634.2020.1801974 32723108!ä!32723108 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Dermatolog+Treat 2022 ; 33 (2): 1084-1090 Nephropedia Template TP {{tp|p=32723108|t=2022. The efficacy of rituximab in patients with mucous membrane pemphigoid |pdf=|usr=}}{{32723108}} gab.com Text The efficacy of rituximab in patients with mucous membrane pemphigoid JO: J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32723108 #FOAvip OBJECTIVE: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder with tendency to scarring. Long term immunosuppressive treatment may be required to minimize the consequences of the disease. METHODS: In this retrospective study, we investigated the efficacy of rituximab (RTX) in MMP patients and compare the beneficial effects of early versus late administration of RTX. Medical records of 24 MMP patients who were treated with 500 mg RTX on day 1, then weekly for 4 consecutive weeks were reviewed. RESULTS: Twenty-one patients (87.5%) reached disease control (DC) at the mean interval of 4.95 months (SD: 5.15; range: 1-24) after RTX. Complete remission (CR) with scarring was achieved in 45.8% (n = 11) and 33.3% (n = 8) attained CR without any residual scar (total CR with or without scar 79.1%). Two patients (8.3%) reached partial remission including persistent gingivitis. Only one patient progressed from non-cicatricial to cicatricial MMP despite receiving RTX. 47.6% (n = 10) of patients experienced relapse after achieving DC at a mean interval of 15.2 months (range: 6-30, SD: 7.0). Considerably, earlier the RTX was administered, sooner the DC was obtained (Pearson r = 0.742, p-value < .001). CONCLUSIONS: These results suggest that RTX may prevent further scarring and progression in MMP patients especially if administered early. Twit Text FOAVip The efficacy of rituximab in patients with mucous membrane pemphigoid ????J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32723108 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32723108 #FOAvip English Wikipedia <ref>{{Cite pmid|32723108}}</ref> The efficacy of rituximab in patients with mucous membrane pemphigoid #MMPMID32723108 Amir Dastmalchi D; Moslemkhani S; Bayat M; Balighi K; Abedini R; Mahmoudi H; Daneshpazhooh M J Dermatolog Treat 2022[Mar]; 33 (2): 1084-1090 PMID32723108show ga OBJECTIVE: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder with tendency to scarring. Long term immunosuppressive treatment may be required to minimize the consequences of the disease. METHODS: In this retrospective study, we investigated the efficacy of rituximab (RTX) in MMP patients and compare the beneficial effects of early versus late administration of RTX. Medical records of 24 MMP patients who were treated with 500 mg RTX on day 1, then weekly for 4 consecutive weeks were reviewed. RESULTS: Twenty-one patients (87.5%) reached disease control (DC) at the mean interval of 4.95 months (SD: 5.15; range: 1-24) after RTX. Complete remission (CR) with scarring was achieved in 45.8% (n = 11) and 33.3% (n = 8) attained CR without any residual scar (total CR with or without scar 79.1%). Two patients (8.3%) reached partial remission including persistent gingivitis. Only one patient progressed from non-cicatricial to cicatricial MMP despite receiving RTX. 47.6% (n = 10) of patients experienced relapse after achieving DC at a mean interval of 15.2 months (range: 6-30, SD: 7.0). Considerably, earlier the RTX was administered, sooner the DC was obtained (Pearson r = 0.742, p-value < .001). CONCLUSIONS: These results suggest that RTX may prevent further scarring and progression in MMP patients especially if administered early. |*Pemphigoid, Bullous[MESH] |Humans[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Mucous Membrane[MESH] |Retrospective Studies[MESH] |Rituximab/therapeutic use[MESH]The efficacy of rituximab in patients with mucous membrane pemphigoid (epmc).pdf DeepDyve Pubget Overpricing